Date: 2015-04-13
Type of information: Nomination
Compound:
Company: Halozyme Therapeutics (USA - CA)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On April 13, 2015, Halozyme Therapeutics, a biotechnology company developing novel oncology and drug-delivery therapies, announced the appointment of Harry J. Leonhardt, Esq., as senior vice president, general counsel and chief compliance officer, reporting to Dr. Helen Torley, president and chief executive officer. Mr. Leonhardt brings more than 30 years of corporate legal, intellectual property, compliance, business development and mergers and acquisitions experience to Halozyme, with an extensive background in the biotechnology sector. He most recently served as senior vice president of Legal and Compliance, and corporate secretary for Amylin Pharmaceuticals, a biotech company acquired by Bristol Myers Squibb in 2012. At Halozyme, he will be responsible for all legal, compliance and intellectual property matters. Prior to joining Amylin, Mr. Leonhardt served as senior vice president, general counsel and corporate secretary for Senomyx; executive vice president of Business Development, general counsel and corporate secretary at Genoptix, Inc.; and senior vice president, general counsel and secretary for Nanogen, Inc. He also held positions of increasing responsibility at Allergan, Inc. including head of worldwide litigation and general counsel for European Operations. Early in his career, Mr. Leonhardt was an attorney at the Los Angeles office of Lyon & Lyon where he represented a number of prominent clients in the biotechnology and pharmaceutical industries. He received his Bachelor of Science degree from the University of the Sciences in Philadelphia and his Juris Doctorate from the University of Southern California Law Center.
Financial terms:
Latest news:
